INCLISIRAN: A SYSTEMATIC REVIEW OF THE BENEFITS OF PROMISING LIPID-LOWERING IN THE TREATMENT OF DYSLIPIDEMIAS

• DOI: 10.22533/at.ed.1592642220104

• Palavras-chave: Dyslipidemia; Inclisiran; PCSK9.

• Keywords: Dyslipidemia; Inclisiran; PCSK9.

• Abstract:

  Objective: To evaluate the reduction of negative outcomes and increase in survival with the new lipid-lowering therapy on the market, as well as its superiority in relation to other drugs, having as a fundamental principle of management the reduction of LDL cholesterol levels. Methods: An integrative review was carried out, using as criteria the search in the National Library of Medicine (PubMed) and Scientific Electronic Library Online (SciELO) databases using the descriptors (i) inclisiran (ii) PCSK9, (iii) dyslipidemias with the Boolean operator “AND”. Studies published from 2018 to 2022 were included. Results: The approved inclisiran has been shown to reduce LDL cholesterol levels by more than 50%, it also brings as a positive point the factor of durability of the therapy, being proposed as a vaccine for patients with dyslipidemia, the which is an immeasurable advance in cardiology and endocrinology in recent years, not requiring daily doses of medication, which facilitates therapeutic adherence and the reduction of cardiovascular outcomes. With adverse effects, 4.69% of patients who received inclisiran reported an injection site reaction, all reactions were transient, there was no evidence of liver, kidney, muscle or platelet toxicity. Final considerations: PCSK9 inhibitors are a welcome addition to our approaches to reducing LDL-C and cardiovascular events in patients with high levels of dyslipidemia and refractory to conventional treatments.